HALO Halozyme Therapeutics Inc

Halozyme Therapeutics Inc is a biotechnology company. It is engaged in research on human enzymes that alter the extracellular matrix and tumor environment.

$45.96  -1.08 (-2.30%)
As of 06/28/2022 14:07:21 EST     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  Common stocks
Category3:  Mid cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  07/26/2004
Outstanding shares:  137,949,680
Average volume:  1,135,024
Market cap:   $6,469,839,992
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      2975098

---

Valuation   (See tab for details)

---

PE ratio:   14.88
PB ratio:   32.75
PS ratio:   13.72
Return on equity:   167.11%
Net income %:   92.23%